FDA Chief Counsel Troy Resigns; Agency Says It Will Still Support Preemption
Executive Summary
FDA will continue to protect its regulatory authority by supporting federal preeminence in state product liability suits following the departure of Chief Counsel Dan Troy, Acting Commissioner Lester Crawford said
You may also be interested in...
FDARA Citizen Petition Provisions No “Silver Bullet,” Bradshaw Tells GPhA
Provisions in FDA reform legislation that aim to limit the impact of citizen petitions on generic drug approvals are unlikely to provide the relief the generic industry seeks, according to outgoing FDA Chief Counsel Sheldon Bradshaw
FDARA Citizen Petition Provisions No “Silver Bullet,” Bradshaw Tells GPhA
Provisions in FDA reform legislation that aim to limit the impact of citizen petitions on generic drug approvals are unlikely to provide the relief the generic industry seeks, according to outgoing FDA Chief Counsel Sheldon Bradshaw
FDA Makes Preemption Case Once And For All In Final Labeling Rule
The product liability preemption language in FDA's physician labeling rule applies to all drugs regardless of whether they are regulated by the final rule